Drug Trial Radar · NCT06244485
A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
210
Planned (sponsor's estimate)
Start
Feb 22, 2024
Primary completion
Nov 1, 2028
Study completion Nov 1, 2028
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Feb 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, and efficacy of valemetostat tosylate in combination with DXd antibody-drug conjugates (ADC) in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
Valemetostat tosylateDrug
Administered orally once daily
T-DXdDrug
One IV infusion Q3W on Day 1 of each 21-day cycle
Dato-DXdDrug
One IV infusion Q3W on Day 1 of each 21-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Reporting Dose-limiting Toxicities (Part 1 Dose Escalation)Time frame: Cycle 1 Day 1 up to Day 21 (each cycle is 21 days)
- Number of Participants Reporting Treatment-emergent Adverse Events (Part 1 Dose Escalation)Time frame: Screening up to 40 days after last dose, up to approximately 5 years
- Objective Response Rate Based on Investigator Assessment (Part 2 Dose Expansion)Time frame: Baseline (Screening), at every 6 weeks from Cycle 1 Day 1 in the first year, and every 12 weeks thereafter until disease progression or until the start of a new anticancer treatment, up to approximately 5 years
Locations
35 sites in 4 countries. Site status is shown where the registry gives one.
City of Hope At Orange County Lennar Foundation Cancer Center
Irvine, California
Sharp Memorial Hospital
San Diego, California
Brcr Medical Center, Inc Dba Boca Raton Clinical Research
Plantation, Florida
University of Hawaii At Manoa
Honolulu, Hawaii
University of Chicago Medical Center
Chicago, Illinois
Dana-Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan-Kettering Cancer Center (Mskcc) - New York
New York, New York
Clinical Research Alliance
Westbury, New York
Unc Hospitals
Chapel Hill, North Carolina
The Cleveland Clinic Foundation
Cleveland, Ohio
Providence Portland Medical Center
Portland, Oregon
Mary Crowley Cancer Research Centers
Dallas, Texas
Ut Southwestern Medical Center
Dallas, Texas
University of Texas M. D. Anderson Cancer Center
Houston, Texas
Next Virginia
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Peking University Third Hospital
Beijing, China
Sun Yat-Sen University, Cancer Center
Guangzhou, China
SunYat-Sen University Cancer Center
Guangzhou, China
Harbin Medical Univeristy Cancer Hospital
Heilongjiang, China
Hunan Cancer Hospital
Hunan, China
Jilin Cancer Hospital
Jilin City, China
Jinana Center Hosptial
Shandong, China
IRCCS Istituto Scientifico Romagnolo Per
Cesena, Italy
National Cancer Center Hospital
Chūōku, Japan
National Hospital Org-Kyushu Cancer Center
Fukuoka, Japan
National Cancer Center Hospital East
Kashiwa, Japan
The Cancer Institute Hospital of Jfcr
Kōtoku, Japan
Aichi Cancer Center Hospital
Nagoya, Japan
Osaka International Cancer Institute
Osaka, Japan
Kindai University Hospital
Ōsaka-sayama, Japan
Shizuoka Cancer Center
Shizuoka, Japan
Osaka University Hospital
Suita, Japan
Kanagawa Cancer Center
Yokohama, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.